Your browser is no longer supported. Please, upgrade your browser.
Settings
CCXI ChemoCentryx, Inc. daily Stock Chart
CCXI [NASD]
ChemoCentryx, Inc.
Index- P/E54.19 EPS (ttm)0.22 Insider Own5.20% Shs Outstand49.77M Perf Week-3.99%
Market Cap598.73M Forward P/E- EPS next Y-0.86 Insider Trans-16.74% Shs Float29.32M Perf Month-8.03%
Income14.40M PEG- EPS next Q-0.23 Inst Own51.50% Short Float8.20% Perf Quarter-14.80%
Sales83.80M P/S7.14 EPS this Y141.80% Inst Trans4.28% Short Ratio8.78 Perf Half Y117.54%
Book/sh0.52 P/B23.13 EPS next Y8.50% ROA9.00% Target Price16.75 Perf Year46.53%
Cash/sh2.95 P/C4.08 EPS next 5Y- ROE31.60% 52W Range5.42 - 15.08 Perf YTD102.18%
Dividend- P/FCF31.35 EPS past 5Y18.30% ROI19.60% 52W High-20.23% Beta1.64
Dividend %- Quick Ratio2.00 Sales past 5Y72.40% Gross Margin- 52W Low121.96% ATR0.63
Employees66 Current Ratio2.00 Sales Q/Q15.90% Oper. Margin15.30% RSI (14)49.63 Volatility5.09% 5.05%
OptionableYes Debt/Eq0.18 EPS Q/Q-54.70% Profit Margin17.20% Rel Volume1.04 Prev Close11.50
ShortableYes LT Debt/Eq0.18 EarningsMay 09 AMC Payout0.00% Avg Volume273.98K Price12.03
Recom2.00 SMA20-2.47% SMA502.18% SMA20027.94% Volume286,040 Change4.61%
May-02-18Initiated H.C. Wainwright Buy $20
Feb-21-17Initiated JMP Securities Mkt Outperform
May-18-15Upgrade JP Morgan Neutral → Overweight
May-20-13Reiterated Stifel Buy $16 → $20
Nov-14-12Initiated Stifel Nicolaus Buy $16
Jun-22-18 09:53AM  ChemoCentryx, 58.com, Seagate, Garmin and Texas Instruments as Zacks Bull and Bear of the Day Zacks
07:00AM  Bull of the Day: ChemoCentryx (CCXI) Zacks
Jun-14-18 01:15PM  4 Top-Ranked Nasdaq Stocks That Have Doubled This Year InvestorPlace
Jun-06-18 08:54AM  Nektar Therapeutics (NKTR) Jumps: Stock Rises 6.5% Zacks
Jun-04-18 08:20AM  Report: Exploring Fundamental Drivers Behind Mitel Networks, Celestica, CoreCivic, Inc., Jazz Pharmaceuticals, Open Text, and ChemoCentryx New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire -6.94%
May-30-18 08:30AM  ChemoCentryx to Present at Two Upcoming Investor Conferences GlobeNewswire
May-23-18 08:30AM  ChemoCentryx Announces Two Upcoming Presentations at the 55th ERA-EDTA Congress GlobeNewswire
May-17-18 10:07AM  Can The Uptrend Continue for ChemoCentryx (CCXI)? Zacks
May-16-18 08:00AM  Better Know Biotech: 2 Stocks You Ought to Know About Motley Fool +9.36%
May-14-18 11:51PM  Edited Transcript of CCXI earnings conference call or presentation 9-May-18 9:00pm GMT Thomson Reuters StreetEvents
May-09-18 07:28PM  ChemoCentryx: 1Q Earnings Snapshot Associated Press
04:05PM  ChemoCentryx Reports First Quarter 2018 Financial Results and Recent Highlights GlobeNewswire
May-02-18 08:30AM  ChemoCentryx to Hold First Quarter 2018 Financial Results Conference Call on Wednesday, May 9, 2018 GlobeNewswire
Apr-19-18 07:40AM  Free Research Report as ChemoCentryxs Quarterly Revenues Zoomed More than 1000%; Turned Profitable Y-O-Y ACCESSWIRE
Apr-12-18 06:07PM  Should You Be Tempted To Sell ChemoCentryx Inc (NASDAQ:CCXI) At Its Current PE Ratio? Simply Wall St.
Apr-11-18 04:05PM  ChemoCentryx Announces Presentation During National Kidney Foundation 2018 Spring Clinical Meeting GlobeNewswire
Apr-10-18 07:45AM  Recent Analysis Shows Ericsson, Toronto Dominion Bank, Odonate Therapeutics, Colliers International Group, ChemoCentryx, and CyberArk Software Market Influences Renewed Outlook, Key Drivers of Growth GlobeNewswire
Apr-04-18 03:43PM  Can ChemoCentryx Inc (NASDAQ:CCXI) Continue To Outperform Its Industry? Simply Wall St. +5.96%
Apr-03-18 08:30AM  ChemoCentryx to Present at Two Upcoming Investor Conferences GlobeNewswire
Apr-02-18 07:40AM  Wired News Exelixis Partner Ipsen Gets EMA Validation of the Application for a New Indication for CABOMETYX ACCESSWIRE -9.34%
Mar-22-18 08:30AM  ChemoCentryx Publishes Novel Findings of Role of CCR2 in Kidney Glomerulus, Supporting Advancement of CCR2 Inhibitor CCX140 in the Treatment of Focal Segmental Glomerulosclerosis (FSGS) GlobeNewswire
Mar-11-18 07:05PM  Edited Transcript of CCXI earnings conference call or presentation 9-Mar-18 1:30pm GMT Thomson Reuters StreetEvents
Mar-10-18 08:22PM  ChemoCentryx (CCXI) Q4 2017 Earnings Conference Call Transcript Motley Fool
Mar-09-18 11:22AM  ChemoCentryx Inc (NASDAQ:CCXI): When Will It Breakeven? Simply Wall St. +11.94%
07:41AM  ChemoCentryx posts 4Q profit Associated Press
07:00AM  ChemoCentryx Reports Fourth Quarter and Full Year 2017 Financial Results and Recent Highlights GlobeNewswire
06:30AM  Chemocentryx, Inc. to Host Earnings Call ACCESSWIRE
Mar-06-18 08:30AM  ChemoCentryx to Present at the Cowen and Company 38th Annual Health Care Conference GlobeNewswire
Mar-01-18 08:30AM  ChemoCentryx to Hold Fourth Quarter 2017 Financial Results Conference Call on Friday, March 9, 2018 GlobeNewswire
Jan-22-18 05:00PM  ChemoCentryx Announces Positive Overall Survival Results with CCR2 Inhibitor CCX872 for Locally Advanced/Metastatic Pancreatic Cancer GlobeNewswire
Jan-08-18 08:30AM  ChemoCentryx Strengthens Senior Executive Team with the Appointment of William Fairey as Executive Vice President and Chief Operating Officer GlobeNewswire
Jan-06-18 10:34AM  3 Biotech Stocks That Soared This Week: Are They Buys? Motley Fool
Jan-04-18 12:11PM  Here's Why ChemoCentryx Rose as Much as 53.5% Today Motley Fool +39.42%
07:05AM  ChemoCentryx Secures up to $100 Million in New Capital Commitments GlobeNewswire
07:00AM  Avacopan Conditional Marketing Authorization Application Accepted for Regulatory Review by European Medicines Agency GlobeNewswire
01:00AM  AVACOPAN CONDITIONAL MARKETING AUTHORIZATION APPLICATION ACCEPTED FOR REGULATORY REVIEW BY EUROPEAN MEDICINES AGENCY GlobeNewswire
Jan-03-18 08:30AM  ChemoCentryx to Present at the 36th Annual J.P. Morgan Healthcare Conference GlobeNewswire
Dec-28-17 11:55AM  ETFs with exposure to ChemoCentryx, Inc. : December 28, 2017 Capital Cube +6.49%
Dec-27-17 08:41AM  ChemoCentryx, Inc. :CCXI-US: Earnings Analysis: Q3, 2017 By the Numbers : December 27, 2017 Capital Cube
Nov-27-17 05:30PM  Should You Buy ChemoCentryx Inc (CCXI) Now? Simply Wall St.
Nov-18-17 08:56AM  Edited Transcript of CCXI earnings conference call or presentation 7-Nov-17 10:00pm GMT Thomson Reuters StreetEvents
Nov-17-17 08:30AM  ChemoCentryx to Participate at the Piper Jaffray 29th Annual Healthcare Conference GlobeNewswire
Nov-10-17 01:06PM  ChemoCentryx, Inc. Value Analysis (NASDAQ:CCXI) : November 10, 2017 Capital Cube
Nov-09-17 12:18PM  ETFs with exposure to ChemoCentryx, Inc. : November 9, 2017 Capital Cube
07:20AM  ChemoCentryx, Inc. breached its 50 day moving average in a Bullish Manner : CCXI-US : November 9, 2017 Capital Cube
Nov-07-17 05:49PM  ChemoCentryx reports 3Q loss Associated Press
04:40PM  ChemoCentryx Reports Third Quarter 2017 Financial Results and Recent Highlights GlobeNewswire
Nov-03-17 08:31AM  Presentations at ASN Kidney Week 2017 Highlight ChemoCentryx Platform in Treatment of Kidney Diseases ANCA-Associated Vasculitis and Focal Segmental Glomerulosclerosis (FSGS) GlobeNewswire
Nov-01-17 08:30AM  ChemoCentryx to Hold Third Quarter 2017 Financial Results Conference Call on Tuesday, November 7, 2017 GlobeNewswire
Oct-20-17 08:26AM  ChemoCentryx, Inc. breached its 50 day moving average in a Bearish Manner : CCXI-US : October 20, 2017 Capital Cube
Oct-16-17 09:49AM  ETFs with exposure to ChemoCentryx, Inc. : October 16, 2017 Capital Cube
Oct-05-17 10:55AM  ETFs with exposure to ChemoCentryx, Inc. : October 5, 2017 Capital Cube
Oct-04-17 09:21AM  ChemoCentryx, Inc. :CCXI-US: Earnings Analysis: Q2, 2017 By the Numbers : October 4, 2017 Capital Cube
Oct-03-17 08:14AM  ChemoCentryx, Inc. breached its 50 day moving average in a Bullish Manner : CCXI-US : October 3, 2017 Capital Cube
Oct-02-17 05:27PM  All You Need To Know About ChemoCentryx Incs (CCXI) Risks Simply Wall St. +6.87%
Sep-15-17 08:37PM  Is There Now An Opportunity In ChemoCentryx Inc (CCXI)? Simply Wall St.
Sep-05-17 08:30AM  ChemoCentryx to Present at Three Upcoming Investor Conferences GlobeNewswire
Aug-21-17 05:55PM  ChemoCentryx, Inc. Value Analysis (NASDAQ:CCXI) : August 21, 2017 Capital Cube
Aug-14-17 02:11AM  Edited Transcript of CCXI earnings conference call or presentation 8-Aug-17 9:00pm GMT Thomson Reuters StreetEvents
Aug-10-17 09:38AM  ChemoCentryx, Inc. breached its 50 day moving average in a Bearish Manner : CCXI-US : August 10, 2017 Capital Cube -5.61%
01:07AM  ChemoCentryx reports 2Q loss Associated Press
Aug-08-17 04:05PM  ChemoCentryx Reports Second Quarter 2017 Financial Results and Recent Highlights GlobeNewswire
01:10PM  Investor Network: Chemocentryx, Inc. to Host Earnings Call ACCESSWIRE
Jul-26-17 08:30AM  ChemoCentryx to Hold Second Quarter 2017 Financial Results Conference Call on Tuesday, August 8, 2017 GlobeNewswire
Jul-18-17 07:29AM  New Strong Buy Stocks for July 18th Zacks
Jul-12-17 08:15AM  ChemoCentryx (CCXI) Catches Eye: Stock Moves Up 6.4% Zacks +5.18%
Jun-15-17 01:27PM  ETFs with exposure to ChemoCentryx, Inc. : June 15, 2017 Capital Cube
Jun-08-17 08:07AM  ChemoCentryx, Inc. breached its 50 day moving average in a Bullish Manner : CCXI-US : June 8, 2017 Capital Cube
Jun-06-17 07:30AM  Oral Presentations at ERA-EDTA Congress Highlight Fourth Potential Indication for Avacopan and Potential for CCR2 Inhibition in Focal Segmental Glomerulosclerosis (FSGS) GlobeNewswire
May-24-17 08:30AM  ChemoCentryx to Present at Two Upcoming Investor Conferences GlobeNewswire
May-23-17 08:30AM  ChemoCentryx Granted EU Orphan Drug Designation for Avacopan in the Treatment of Debilitating Kidney Disease C3 Glomerulopathy (C3G) GlobeNewswire
May-16-17 01:10PM  Edited Transcript of CCXI earnings conference call or presentation 10-May-17 9:00pm GMT Thomson Reuters StreetEvents
May-15-17 05:07PM  ChemoCentryx, Inc. Value Analysis (NASDAQ:CCXI) : May 15, 2017 Capital Cube
May-12-17 08:15AM  ChemoCentryx, Inc. breached its 50 day moving average in a Bullish Manner : CCXI-US : May 12, 2017 Capital Cube
May-11-17 08:51PM  Edited Transcript of CCXI earnings conference call or presentation 10-May-17 9:00pm GMT Thomson Reuters StreetEvents +6.21%
May-10-17 04:50PM  ChemoCentryx reports 1Q loss Associated Press
04:05PM  ChemoCentryx Reports First Quarter 2017 Financial Results GlobeNewswire
11:30AM  Investor Network: Chemocentryx, Inc. to Host Earnings Call Accesswire
Apr-27-17 08:30AM  ChemoCentryx to Hold First Quarter 2017 Financial Results Conference Call on Wednesday, May 10, 2017 GlobeNewswire
Apr-06-17 08:27AM  ChemoCentryx, Inc. breached its 50 day moving average in a Bearish Manner : CCXI-US : April 6, 2017 Capital Cube
Mar-24-17 08:14AM  ChemoCentryx, Inc. breached its 50 day moving average in a Bearish Manner : CCXI-US : March 24, 2017
Mar-22-17 08:30AM  ChemoCentryx Receives FDA Orphan Drug Designation for Avacopan in the Treatment of Debilitating Kidney Disease C3 Glomerulopathy (C3G) GlobeNewswire
Mar-18-17 01:04PM  CHEMOCENTRYX, INC. Financials
Mar-17-17 10:11AM  ChemoCentryx (CCXI) Shares March Higher, Can It Continue? Zacks
Mar-15-17 03:04PM  Edited Transcript of CCXI earnings conference call or presentation 14-Mar-17 9:00pm GMT Thomson Reuters StreetEvents +9.27%
Mar-14-17 05:00PM  ChemoCentryx reports 4Q loss Associated Press
04:32PM  CHEMOCENTRYX, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibi
04:05PM  ChemoCentryx Reports Fourth Quarter and Full Year 2016 Financial Results GlobeNewswire
07:07AM  Q4 2016 ChemoCentryx Inc Earnings Release - After Market Close
Mar-10-17 09:29AM  Biotech Premarket Movers: ChemoCentryx, Jazz, Ionis, Zogenix TheStreet.com
Mar-03-17 10:10AM  Sio Capital Remains Bullish On These Stocks Despite Weak Performance Insider Monkey
Mar-02-17 04:32PM  CHEMOCENTRYX, INC. Files SEC form 8-K, Change in Directors or Principal Officers
Mar-01-17 08:30AM  ChemoCentryx to Hold Fourth Quarter 2016 Financial Results Conference Call on Tuesday, March 14, 2017 GlobeNewswire
Feb-28-17 08:30AM  ChemoCentryx to Present at the Cowen and Company 37th Annual Health Care Conference GlobeNewswire
Feb-21-17 08:16AM  Coverage initiated on ChemoCentryx by JMP Securities
Feb-14-17 04:18PM  CHEMOCENTRYX, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement
07:00AM  Vifor Pharma and ChemoCentryx Announce Expansion of Avacopan Agreement for Rare Renal Diseases GlobeNewswire
Jan-20-17 03:30PM  ChemoCentryx Announces Presentation of Data from Ongoing Phase Ib Clinical Trial of CCR2 Inhibitor CCX872 in Patients with Advanced Non-Resectable Pancreatic Cancer GlobeNewswire
10:00AM  ChemoCentryx, Inc. (Nasdaq: CCXI) to Ring The Nasdaq Stock Market Closing Bell Remotely from the Nasdaq Entrepreneurial Center in San Francisco GlobeNewswire
Jan-19-17 07:35AM  ChemoCentryx, Inc. breached its 50 day moving average in a Bullish Manner : CCXI-US : January 19, 2017
ChemoCentryx, Inc., a clinical-stage biopharmaceutical company, develops new medications for inflammatory and autoimmune diseases, and cancer in the United States. The company targets the chemokine and chemoattractant systems to discover, develop, and commercialize orally-administered therapies. Its lead drug candidate is Avacopan, an orally-administered complement inhibitor of the complement C5a receptor (C5aR), is in Phase III development for the treatment of anti-neutrophil cytoplasmic auto-antibody-associated vasculitis (AAV). The company is also developing Avacopan for the treatment of patients with C3 glomerulopathy (C3G), hidradenitis suppurativa (HS), and in atypical hemolytic uremic syndrome (aHUS). In addition, the company is developing CCX140, an inhibitor of the chemokine receptor known as CCR2, which has completed a Phase II clinical trial in diabetic nephropathy (DN) and is being developed for patients with focal segmental glomerulosclerosis (FSGS). Further, it has early stage drug candidates that target chemoattractant receptors in other inflammatory and autoimmune diseases, and in cancer. The company was founded in 1997 and is headquartered in Mountain View, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Parker Geoffrey M.DirectorMay 25Option Exercise0.0012,912058,583May 30 05:13 PM
Schall Thomas J.President and CEOMay 23Option Exercise6.0027,928167,5682,212,922May 23 09:53 PM
Schall Thomas J.President and CEOMay 23Sale13.0127,928363,2932,184,994May 23 09:53 PM
Schall Thomas J.President and CEOMay 22Option Exercise6.0030,932185,5922,215,926May 23 09:53 PM
Schall Thomas J.President and CEOMay 22Sale13.0030,932402,1502,184,994May 23 09:53 PM
Cappel Markus J.Chief Bus. Officer & TreasurerMay 21Option Exercise6.002,70916,25426,535May 23 09:52 PM
Schall Thomas J.President and CEOMay 21Option Exercise6.0033,938203,6282,218,932May 23 09:53 PM
Schall Thomas J.President and CEOMay 21Sale12.5533,938426,0222,184,994May 23 09:53 PM
Cappel Markus J.Chief Bus. Officer & TreasurerMay 21Sale13.002,70935,21723,826May 23 09:52 PM
Schall Thomas J.President and CEOMay 17Option Exercise6.0017,798106,7882,202,792May 17 07:38 PM
Schall Thomas J.President and CEOMay 17Sale12.1417,798216,1372,184,994May 17 07:38 PM
Cappel Markus J.Chief Bus. Officer & TreasurerMay 16Option Exercise6.0050,000300,00057,160May 17 07:34 PM
Schall Thomas J.President and CEOMay 16Option Exercise6.0082,202493,2122,267,196May 17 07:38 PM
Schall Thomas J.President and CEOMay 16Sale12.2682,2021,007,6652,184,994May 17 07:38 PM
Cappel Markus J.Chief Bus. Officer & TreasurerMay 16Sale11.8150,000590,63723,826May 17 07:34 PM
KANAYA SUSAN MEVP, CFO and Sec.May 15Option Exercise6.008,30649,83646,441May 17 07:29 PM
Schall Thomas J.President and CEOMay 15Option Exercise6.00100,000600,0002,284,994May 17 07:38 PM
Schall Thomas J.President and CEOMay 15Sale11.32100,0001,132,0602,184,994May 17 07:38 PM
KANAYA SUSAN MEVP, CFO and Sec.May 15Sale11.148,30692,52638,135May 17 07:29 PM
KANAYA SUSAN MEVP, CFO and Sec.May 08Option Exercise6.0065,328391,968103,463May 10 07:05 PM
KANAYA SUSAN MEVP, CFO and Sec.May 08Sale11.5365,328752,92538,135May 10 07:05 PM
Cappel Markus J.Chief Bus. Officer & TreasurerMay 02Option Exercise6.0038,089228,53461,915May 03 08:29 PM
KANAYA SUSAN MEVP, CFO and Sec.May 02Option Exercise6.001,3668,19639,501May 04 05:36 PM
Schall Thomas J.President and CEOMay 02Option Exercise6.0032,873197,2382,217,867May 03 08:38 PM
Schall Thomas J.President and CEOMay 02Sale11.0332,873362,4512,184,994May 03 08:38 PM
KANAYA SUSAN MEVP, CFO and Sec.May 02Sale11.501,36615,70938,135May 04 05:36 PM
Cappel Markus J.Chief Bus. Officer & TreasurerMay 02Sale11.0238,089419,88623,826May 03 08:29 PM
Cappel Markus J.Chief Bus. Officer & TreasurerMay 01Option Exercise6.0011,91171,46635,737May 03 08:29 PM
Schall Thomas J.President and CEOMay 01Option Exercise6.0017,127102,7622,202,121May 03 08:38 PM
Schall Thomas J.President and CEOMay 01Sale11.0017,127188,4072,184,994May 03 08:38 PM
Cappel Markus J.Chief Bus. Officer & TreasurerMay 01Sale11.0011,911131,02723,826May 03 08:29 PM
Schall Thomas J.President and CEOJan 01Option Exercise0.0066,66602,221,711Jan 03 07:47 PM
KANAYA SUSAN MEVP, CFO and Sec.Jan 01Option Exercise0.0033,333057,184Jan 03 07:38 PM
Cappel Markus J.Chief Bus. Officer & TreasurerJan 01Option Exercise0.0018,333034,724Jan 03 07:31 PM
SINGH RAJINDERSVP, ResearchJan 01Option Exercise0.0010,000010,000Jan 03 07:24 PM
KANAYA SUSAN MEVP, CFO and Sec.Oct 20Option Exercise0.0033,333042,610Oct 24 05:21 PM
LUCAS ROGER CDirectorAug 01Sale10.072,25022,66793,846Aug 03 06:11 PM
Edwards Thomas A.DirectorJul 28Option Exercise0.006,7670138,785Aug 01 06:17 PM
Bekker PetrusChief Medical OfficerJul 13Option Exercise7.9316,013126,90971,964Jul 13 07:46 PM
Bekker PetrusChief Medical OfficerJul 13Sale10.2116,013163,46459,839Jul 13 07:46 PM
Bekker PetrusChief Medical OfficerJul 12Option Exercise6.7330,000201,87469,839Jul 13 07:46 PM
Bekker PetrusChief Medical OfficerJul 12Sale9.9830,000299,28059,839Jul 13 07:46 PM
Bekker PetrusChief Medical OfficerJul 11Option Exercise6.7830,000203,32683,715Jul 13 07:46 PM
Bekker PetrusChief Medical OfficerJul 11Sale9.7830,000293,32659,839Jul 13 07:46 PM
Bekker PetrusChief Medical OfficerJul 10Option Exercise6.302901,82760,129Jul 10 07:59 PM
Bekker PetrusChief Medical OfficerJul 10Sale9.302902,69759,839Jul 10 07:59 PM
Bekker PetrusChief Medical OfficerJul 07Option Exercise6.3019,587123,39879,426Jul 10 07:59 PM
Bekker PetrusChief Medical OfficerJul 07Sale9.3019,587182,15959,839Jul 10 07:59 PM
Bekker PetrusChief Medical OfficerJun 30Option Exercise6.6230,000198,59377,848Jun 30 07:32 PM
Bekker PetrusChief Medical OfficerJun 30Sale9.2330,000276,87059,839Jun 30 07:32 PM
Bekker PetrusChief Medical OfficerJun 29Option Exercise7.105,50939,11465,348Jun 30 07:32 PM
Bekker PetrusChief Medical OfficerJun 29Sale9.115,50950,16759,839Jun 30 07:32 PM
Bekker PetrusChief Medical OfficerJun 28Option Exercise7.1030,000213,00089,839Jun 30 07:32 PM
Bekker PetrusChief Medical OfficerJun 28Sale9.1230,000273,66959,839Jun 30 07:32 PM